Sugi Predict

Sugi Predict / Compounds / SCHEMBL1015154

SCHEMBL1015154

SCHEMBL1015154

CCOC(=O)CC(=O)CC1CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.54
▸ MGAM O43451 1/20 0.54
▸ SI P14410 1/20 0.54
▸ MGAM2 Q2M2H8 1/20 0.54
▸ ALDH1A1 P00352 2/20 0.40
▸ TRPA1 O75762 1/20 0.40
▸ SMYD3 Q9H7B4 1/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ EPHX2 P34913 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ JAK1 P23458 1/20 0.36
▸ TYK2 P29597 1/20 0.36
▸ JAK3 P52333 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24696141 0.94 GAA (0.48) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL24696377 0.93 GAA (0.47) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL3109485 0.92 GAA (0.50) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL2555598 0.92 MGAM (0.50) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL24696247 0.91 GAA (0.45) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL3106991 0.91 MGAM (0.48) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL6160915 0.91 MGAM (0.48) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL1021852 0.90 MEN1 (0.49) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL2408506 0.88 MGAM (0.45) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL24695618 0.87 GAA (0.41) GAAMGAMSIMGAM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4744661-A2 NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2026-05-20 — — EP disclosed
EP-4298092-B1 NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2025-11-26 — — EP disclosed
WO-2025136936-A1 AGONISTS OF TREM2 ACTIVITY MERCK SHARP & DOHME LLC (US) 2025-06-26 — — WO disclosed
CN-115996924-B Substituted pyrazolyl compounds and methods of use thereof 诺华医药股份公司 2025-03-07 — — CN disclosed
US-20240025883-A1 PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2024-01-25 — — US disclosed
EP-4298092-A1 NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-01-03 — — EP disclosed
CN-116829550-A Pyrimidine-2-ylsulfonamide derivatives 豪夫迈·罗氏有限公司 2023-09-29 — — CN disclosed
CN-113620941-B Cyclopropyl-pyrazole derivatives and their use in agriculture 宁夏苏融达化工有限公司 2023-07-14 — — CN disclosed
US-20230183228-A1 SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF NOVARTIS PHARMA AG (CH) 2023-06-15 — — US disclosed
US-20230183228-A1 SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF NOVARTIS PHARMA AG (CH) 2023-06-15 — — US disclosed
EP-2074117-A2 HETEROMONOCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-07-01 — — EP disclosed
WO-2009068512-A1 2 -AMINO-PYRIMIDINE DERIVATIVES AS HISTAMINE H4 ANTAGONISTS PALAU PHARMA, S. A. (ES) 2009-06-04 — — WO disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 — — US disclosed
US-20080207654-A1 HETEROMONOCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2008-08-28 — — US disclosed
WO-2008062905-A2 HETEROMONOCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-29 — — WO disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 — — EP disclosed
US-7217730-B2 Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus WYETH (US) 2007-05-15 — — US disclosed
EP-1509225-A1 METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS Wyeth (US) 2005-03-02 — — EP disclosed
US-20040082643-A1 Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus WYETH (US) 2004-04-29 — — US disclosed
WO-2003099275-A1 METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS WYETH (US) 2003-12-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082643-A1 Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus HAVCR2, HCCS, ZC3HAV1 GAA 4301/4885MGAM 4346/4885SI 2467/4885
US-20080207654-A1 HETEROMONOCYCLIC COMPOUND AND USE THEREOF C1R, C3AR1, C1S GAA 4383/4885MGAM 4369/4885SI 3990/4885
US-20240025883-A1 PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES GPR17, GPR27, GPR119 GAA 1897/4885MGAM 4600/4885SI 3986/4885
US-20230183228-A1 SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF LDHA, LDHB, XDH GAA 45/4885MGAM 181/4885SI 96/4885
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 GAA 4817/4885MGAM 4848/4885SI 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.